Med BioGene Inc. (MBI) is a Canadian-based life science company. The Company is engaged in the development and commercialization of genomic-based clinical laboratory diagnostic tests for cancer. It’s focus is on managing the license and rights to GeneFx Lung (formerly, LungExpress Dx), a gene expression-based test for early-stage non-small-cell lung cancer. GeneFx Lung is expected to provide better-informed and personalized treatment decisions to assist in the selection of patients for adjuvant chemotherapy. MBI has partnered with Precision Therapeutics for the global commercialization of GeneFx Lung.